Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RELIPIC 1MG/G GEL - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/RELIPIC 1MG/G GEL

Approved

STANDARD

RELIPIC 1MG/G GEL

Towa Pharmaceutical S.A.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Oct 29, 2025
Approval ID: 15e32962ae1b88ba
Company: Towa Pharmaceutical S.A.
Type: Standard

Approval Details

Approval Id: 15e32962ae1b88ba
Drug Cima Aemps Name: RELIPIC 1MG/G GEL
Register Number: 90715
Holder Company Name: Towa Pharmaceutical S.A.
Marketing Company Name: Towa Pharmaceutical S.A.
Authorization Date: 2025-10-29
Dosage Form: GEL
Dose: 1 mg/g
Route Of Administration: USO CUTÁNEO
Prescription Type: Sin Receta
Commercialized: No
Company Name: Towa Pharmaceutical S.A.

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Oct 29, 2025

Approval ID

15e32962ae1b88ba

Type

Standard

Back to CIMA-AEMPS Approvals